Akums Drugs

When is the next results date for Akums Drugs?

No Upcoming Board Meetings

Has Akums Drugs declared dividend?

No Dividend History Available

Who are the peers of the Akums Drugs?

Akums Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Shilpa Medicare, Aarti Pharma, Strides Pharma, FDC, and SPARC. In terms of management risk, growth, and capital structure, Sun Pharma and Cipla are top performers, while Akums Drugs shows average management risk and below-average growth.

Peers: The peers of Akums Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Shilpa Medicare, Aarti Pharma, Strides Pharma, FDC, and SPARC.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Akums Drugs, Shilpa Medicare, Aarti Pharma, and FDC. Below Average management risk is noted for Strides Pharma and SPARC. For Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is reported for Akums Drugs, Divi's Lab., Torrent Pharma, Shilpa Medicare, Aarti Pharma, Strides Pharma, and FDC. Finally, Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, and Aarti Pharma, while Good capital structure is noted for Torrent Pharma and Akums Drugs, and Below Average capital structure is seen at Shilpa Medicare, Strides Pharma, and SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is SPARC at -7.40%. Akums Drugs does not have a 1-year return available for comparison. Additionally, the peers with negative six-month returns include Torrent Pharma, FDC, and SPARC.

Is Akums Drugs overvalued or undervalued?

As of May 28, 2025, Akums Drugs is considered an attractive investment due to its undervalued status, with a PE ratio of 27.65, lower than peers like Sun Pharmaceutical and Divi's Laboratories, despite a year-to-date return of -11.07% compared to the Sensex's 5.54%.

As of 28 May 2025, the valuation grade for Akums Drugs has moved from does not qualify to attractive, indicating a significant improvement in its investment appeal. The company is currently assessed as undervalued. Key ratios include a PE ratio of 27.65, an EV to EBITDA of 18.09, and a ROCE of 12.16%. <BR><BR>In comparison to its peers, Akums Drugs has a lower PE ratio than Sun Pharmaceutical Industries Ltd., which stands at 35.25, and Divi's Laboratories Ltd., which is at 79.33. Other attractive peers include Cipla Ltd. with a PE of 22.99 and Dr. Reddy's Laboratories Ltd. at 19.49, further supporting the notion that Akums Drugs is undervalued within its sector. Despite a recent underperformance compared to the Sensex, with a year-to-date return of -11.07% against the Sensex's 5.54%, the company's valuation metrics suggest a favorable investment opportunity.

What does Akums Drugs do?

Akums Drugs and Pharmaceuticals Ltd is a mid-cap pharmaceutical CDMO, incorporated in 2004, with net sales of ₹10,556 Cr and a net profit of ₹1,476 Cr as of March 2025. The company has a market cap of ₹8,828 Cr and a P/E ratio of 27.00.

Overview: <BR>Akums Drugs and Pharmaceuticals Ltd is a pharmaceutical contract development and manufacturing organization (CDMO) operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>History: <BR>The company was incorporated on April 19, 2004, and received its Certificate for Commencement of Business on May 13, 2004. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 10,556 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,476 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 8,828 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.16 <BR>Return on Equity: 10.55% <BR>Price to Book: 2.89 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Akums Drugs?

The top shareholders of Akums Drugs include Akums Master Trust (40.79%), mutual funds (6.11%), foreign institutional investors (5.77%), and Ruby Qc Investment Holdings Pte Ltd (4.62%), with individual investors holding 3.41%. There are no pledged promoter holdings.

The top shareholders of Akums Drugs include the promoters, with Akums Master Trust, represented by Sanjeev Jain and Sandeep Jain, holding the largest share at 40.79%. There are no pledged promoter holdings. Additionally, mutual funds hold a total of 6.11% across 18 schemes, and foreign institutional investors (FIIs) account for 5.77% through 50 different FIIs. The highest public shareholder is Ruby Qc Investment Holdings Pte Ltd, which holds 4.62%. Individual investors collectively own 3.41% of the company.

How big is Akums Drugs?

As of 24th July, Akums Drugs & Pharmaceuticals Ltd has a market capitalization of 8,578.00 Cr, with recent net sales of 4,118.16 Cr and a net profit of 338.18 Cr. Shareholder's funds are 3,047.01 Cr, and total assets are 3,905.38 Cr.

As of 24th July, Akums Drugs & Pharmaceuticals Ltd has a market capitalization of 8,578.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 4,118.16 Cr and a Net Profit of 338.18 Cr.<BR><BR>For the latest annual period ending March 2025, Shareholder's Funds amounted to 3,047.01 Cr, while Total Assets were reported at 3,905.38 Cr.

Is Akums Drugs technically bullish or bearish?

As of October 10, 2025, Akums Drugs shows a mildly bearish trend due to bearish weekly MACD and KST, despite bullish weekly and monthly RSI readings indicating some underlying strength.

As of 10 October 2025, the technical trend for Akums Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST being bearish, alongside daily moving averages indicating a bearish trend. However, the weekly and monthly RSI readings are bullish, suggesting some underlying strength. The Bollinger Bands and OBV are also mildly bearish on a weekly basis. Overall, while there are bullish signals from the RSI, the prevailing indicators lean towards a mildly bearish outlook.

How has been the historical performance of Akums Drugs?

Akums Drugs has shown significant recovery and growth, with net sales reaching 4,118.16 crore in March 2025, up from 3,654.82 crore in March 2023, and a profit after tax of 343.78 crore, recovering from a loss the previous year. The company's financial position is stable, with improved cash flow and earnings per share increasing to 22.09.

Answer:<BR>The historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected this positive trend, reaching 338.18 crore in March 2025, a recovery from a loss of 4.04 crore in March 2024. The company's earnings per share (EPS) improved significantly to 22.09 in March 2025 from -0.28 in March 2024. On the balance sheet, total assets increased to 3,905.38 crore in March 2025 from 3,393.30 crore in March 2024, while total liabilities rose to 3,905.38 crore from 3,393.30 crore, indicating a stable financial position. The cash flow from operating activities also improved to 498 crore in March 2024, compared to 176 crore in March 2023, showcasing better cash generation capabilities. Overall, Akums Drugs demonstrated a strong recovery and growth trajectory in its financial performance over the past few years.

Are Akums Drugs & Pharmaceuticals Ltd latest results good or bad?

Akums Drugs & Pharmaceuticals Ltd's latest results show strong revenue growth and improved net profit, but low return on equity and stock underperformance raise concerns about capital efficiency. Overall, while there are positive signs, the mixed performance suggests caution.

Akums Drugs & Pharmaceuticals Ltd's latest results show a mixed picture. On one hand, the company reported net sales of ₹1,159.59 crores for the December quarter, which reflects a strong sequential growth of 13.96% and a year-on-year increase of 14.76%. Additionally, net profit surged to ₹66.32 crores, marking a significant 62.63% improvement from the previous quarter.<BR><BR>Operating margins also improved, rising to 12.66%, which is a positive sign of operational recovery. However, despite these improvements, the company's return on equity (ROE) remains low at 9.70%, which is below industry standards and raises concerns about capital efficiency. Furthermore, the stock has underperformed the broader market, declining 18.09% over the past year compared to the Sensex's gain of 8.52%.<BR><BR>In summary, while the recent quarterly results indicate operational improvements and revenue growth, the underlying issues related to profitability consistency and capital efficiency continue to pose challenges for the company. This mixed performance suggests that while there are positive signs, significant concerns remain, making the overall assessment somewhat cautious.

Should I buy, sell or hold Akums Drugs & Pharmaceuticals Ltd?

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 31-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is declining, currently at 466.05, reflecting a 1.85% decrease. The stock has underperformed recently, with concerns about management efficiency and growth prospects contributing to its downward trend.

As of 31-Mar, Akums Drugs & Pharmaceuticals Ltd's stock price is falling, currently at 466.05, which reflects a decrease of 8.8 points or 1.85%. The stock has been underperforming, having lost 5.72% over the last two days and opened with a loss of 2.86% today. Additionally, the stock touched an intraday low of Rs 450, marking a decline of 5.23%.<BR><BR>In terms of performance relative to the benchmark, the stock has shown a slight decline of 0.37% over the past week, while the Sensex fell by 1.03%. Over the past month, the stock decreased by 1.73%, compared to a more significant drop of 10.33% in the Sensex. Year-to-date, however, the stock has gained 2.72%, contrasting with a 15.57% decline in the Sensex.<BR><BR>Despite some positive indicators, such as a low Debt to Equity ratio and an increase in institutional investor participation, the overall sentiment appears negative due to poor management efficiency, indicated by a low Return on Equity (ROE) of 9.7%. This suggests low profitability per unit of shareholders' funds, contributing to the stock's downward trend. Furthermore, the company's long-term growth prospects are concerning, with net sales growing at an annual rate of only 6.10% over the last five years. <BR><BR>Overall, the combination of recent price declines, underperformance against the sector, and concerns regarding management efficiency and growth prospects are driving the stock price of Akums Drugs & Pharmaceuticals Ltd lower.

Which are the latest news on Akums Drugs?